{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:41:05Z","timestamp":1788090065677,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,20]]},"DOI":"10.7759\/cureus.99745","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T07:09:01Z","timestamp":1766300941000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Metastatic Renal Cell Carcinoma Developing Isolated Adrenocorticotropic Hormone (ACTH) Deficiency During Nivolumab Therapy"],"prefix":"10.7759","author":[{"given":"Michihiro","family":"Enoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunari","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima H","year":"2019","unstructured":"Arima H, Iwama S, Inaba H, et al.. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J. 2019, 66:581-6. 10.1507\/endocrj.EJ19-0163","journal-title":"Endocr J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi T","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, et al.. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020, 8:10.1136\/jitc-2020-000779","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama S","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014, 6:230ra45. 10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S224791","article-title":"Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies","volume":"12","author":"Tsoli M","year":"2020","unstructured":"Tsoli M, Kaltsas G, Angelousi A, Alexandraki K, Randeva H, Kassi E. Managing ipilimumab-induced hypophysitis: challenges and current therapeutic strategies. Cancer Manag Res. 2020, 12:9551-61. 10.2147\/CMAR.S224791","journal-title":"Cancer Manag Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli P","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al.. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016, 186:3225-35. 10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi G","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019, 14:381-98. 10.1080\/17446651.2019.1701434","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91730","article-title":"Checkpoint on adrenal insufficiency: optimizing screening in immune checkpoint inhibitor therapy","volume":"17","author":"Darapu H","year":"2025","unstructured":"Darapu H, Konindala N, Paluri R. Checkpoint on adrenal insufficiency: optimizing screening in immune checkpoint inhibitor therapy. Cureus. 2025, 17:e91730. 10.7759\/cureus.91730","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103280","article-title":"Anti-PD1 and anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up","volume":"9","author":"Levy M","year":"2020","unstructured":"Levy M, Abeillon J, Dalle S, et al.. Anti-PD1 and anti-PDL1-induced hypophysitis: a cohort study of 17 patients with longitudinal follow-up. J Clin Med. 2020, 9:10.3390\/jcm9103280","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel F","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F, et al.. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015, 172:195-204. 10.1530\/EJE-14-0845","journal-title":"Eur J Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni E","year":"2019","unstructured":"Verzoni E, Carten\u00ec G, Cortesi E, et al.. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer. 2019, 7:99. 10.1186\/s40425-019-0579-z","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02612-1","article-title":"Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan","volume":"29","author":"Yoshimura A","year":"2024","unstructured":"Yoshimura A, Kato T, Nakai Y, et al.. Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan. Int J Clin Oncol. 2024, 29:1916-24. 10.1007\/s10147-024-02612-1","journal-title":"Int J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040860","article-title":"Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"13","author":"Paderi A","year":"2021","unstructured":"Paderi A, Giorgione R, Giommoni E, et al.. Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Cancers (Basel). 2021, 13:10.3390\/cancers13040860","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000299","article-title":"Nivolumab-induced adrenal insufficiency in patients with renal cell carcinoma","volume":"43","author":"Suzuki K","year":"2020","unstructured":"Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Nivolumab-induced adrenal insufficiency in patients with renal cell carcinoma. J Immunother. 2020, 43:38-42. 10.1097\/CJI.0000000000000299","journal-title":"J Immunother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje A","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, et al.. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019, 181:211-9. 10.1530\/EJE-19-0238","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447735-a-case-of-metastatic-renal-cell-carcinoma-developing-isolated-adrenocorticotropic-hormone-acth-deficiency-during-nivolumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T07:09:02Z","timestamp":1766300942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447735-a-case-of-metastatic-renal-cell-carcinoma-developing-isolated-adrenocorticotropic-hormone-acth-deficiency-during-nivolumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.99745","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}